Love Fuels Quest for Life-Saving Gene Therapy

In a remarkable feat of parental love and determination, Jo and Richie Kaur embarked on an unprecedented journey to save their son, Riaan, from Cockayne syndrome, an ultra-rare and fatal genetic disorder. The couple raised $4 million to fund the development of a first-in-human gene therapy.

Riaan, diagnosed at 15 months old, was given a life expectancy of five years. The gene therapy, administered on April 21, 2026, sought to deliver a healthy copy of the CSA gene to his brain, crucial for DNA repair and cellular health.

Navigating the intricate world of drug development, Jo, a civil rights attorney, and Richie established the Riaan Research Initiative. Their efforts involved extensive advocacy, fundraising, and collaboration with scientists, ultimately leading to FDA approval for the experimental treatment.

The decision to proceed was agonizing, given the therapy's experimental nature and Riaan's delicate health. However, after seeking counsel and a sign from Riaan himself, they committed to the procedure, viewing it as Riaan's only chance for a longer, healthier life.

Riaan's gene therapy procedure occurred on April 21, 2026. Following the successful administration, he experienced a brief period of distress but quickly improved. The family is now closely monitoring his progress, hopeful for clinical benefit while acknowledging the unknown future.

The Kaurs' achievement highlights the critical gap in treatments for rare pediatric diseases. They aim to gain FDA approval to treat other children with Cockayne syndrome, emphasizing that no parent should face such a daunting challenge alone.